Study: Price of long-acting PrEP ‘unrealistic’ for population-level HIV control

Back to the "HIV and Co-Infections News" list

The “unrealistic” pricing of long-acting injectable PrEP hinders its use where HIV control budgets are stretched, according to researchers, who found that event-driven oral PrEP is a more cost-effective option for fixed budgets.

Long-acting injectable cabotegravir (CAB-LA) — the first FDA-approved long-acting injectable PrEP — is highly effective and could potentially prevent the most HIV infections globally but is significantly more expensive than oral tenofovir/emtricitabine (TDF/FTC), which limits its potential use, Ishani Sharma, a researcher at the Imperial College London School of Medicine, and Andrew Hill, PhD, senior visiting research fellow at the University of Liverpool, wrote in a study published in Clinical Infectious Diseases.

Sharma and Hill analyzed 98 studies that included 5,230,189 people in 33 countries, evaluating HIV infection rates for five prevention strategies — no PrEP, continuous CAB-LA ($22,200 per person per year), continuous CAB-LA at its target price ($250 per person per year), continuous TDF/FTC ($48 per person per year) and event-driven TDF/FTC ($12 per person per year).

Based on the studies, the researchers determined mean HIV incidence at 2.6 per 100 person-years. The number of people needed to treat to prevent one infection (NNTB) was 42.7 for CAB-LA and 64.1 for continuous and event-driven TDF/FTC.

They estimated that, at the current price, it would cost $949,487 to prevent one HIV infection using continuous CAB-LA, which is more than the annual PrEP budgets for many countries, including some of the top-spending low- and middle-income countries, the researchers noted.

The cost to prevent one infection was $11,453 for CAB-LA at its target price, $4,231 for continuous TDF/FTC and $1,923 for event-driven TDF/FTC.

Based on the analysis, the researchers said event-driven TDF/FTC should be evaluated for wider use to maximize HIV prevention.

“CAB-LA is the most efficacious form of PrEP, but high prices limit numbers who can be treated,” Sharma and Hill wrote. “More HIV infections can be prevented using low-cost, event-driven TDF/FTC as PrEP: far more people can be treated for fixed budgets. This result was consistent across a range of at-risk populations in different countries.”

ViiV Healthcare last year did sign an agreement to allow manufacturing of generic versions of CAB-LA in 90 countries.

Source: Sharma I, et al. Clin Infect Dis. 2023;doi:10.1093/cid/ciad537.

By Stephen Feller


Source : Healio

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.